Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDE TM) and Targeted Removal of Aberrant Protein (TRAP TM) extracellular protein ...
Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results